KJ-C2529 / CARsgen - LARVOL DELTA

In vivo CAR-T product candidates in development (The Manila Times) - "KJ-C2529 is an in vivo CAR T-cell product candidate against CD19/CD20 deploying our CARvivo platform for the treatment of B-cell lymphoma. An IIT is expected to be initiated in 2026 for the treatment of R/R B-NHL."

New trial • B Cell Non-Hodgkin Lymphoma